Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 11, 2026
TickeronGET DAILY SIGNALS
UnitedHealth Group (UNH) Q3 2026 Earnings: What Investors Should Watch

UnitedHealth Group (UNH) Q3 2026 Earnings: What Investors Should Watch

Key Takeaways

  • UnitedHealth Group (UNH) is scheduled to report third quarter 2026 results before the market opens on Tuesday, October 13, 2026.
  • Analysts expect adjusted earnings of roughly $4.12 per share, up sharply from $2.92 in the prior-year quarter.
  • Consensus revenue sits near $111.3 billion, reflecting a modest year-over-year decline tied to ongoing portfolio right-sizing.
  • The company has beaten Wall Street's earnings estimates in each of its last four quarterly reports.
  • Investors will focus on the medical care ratio, Medicare Advantage enrollment trends, and any update to full-year guidance.

Earnings Context and Why It Matters

UnitedHealth Group's quarterly report serves as an important indicator for the managed-care and healthcare-services sector overall. As the largest health insurer in the country, its numbers provide early insights into medical cost trends, Medicare Advantage dynamics, and the effects of Medicaid redeterminations that affect the broader industry. The company approaches this report after a solid stretch, having exceeded consensus estimates in four consecutive quarters while improving margins. With full-year adjusted earnings guidance already lifted to a range of $19.50 to $20.00 per share back in July, this quarter will show whether cost controls and pricing efforts can maintain that progress through the end of the year.

Earnings Expectations

Wall Street anticipates UnitedHealth will post third quarter 2026 adjusted earnings of about $4.12 per share, based on consensus figures from sources such as Zacks and MarketBeat, though some forecasts edge closer to $4.15. This marks a notable increase from $2.92 per share in the same quarter last year, representing growth of more than 40%. Revenue expectations stand at approximately $111.3 billion, which would represent a decline of about 1.6% from $113.2 billion a year earlier due to the company's intentional reduction in certain lower-margin segments.

For additional perspective, UnitedHealth posted adjusted earnings of $6.38 per share on $112.0 billion in revenue during the second quarter of 2026, surpassing estimates by a comfortable margin and lifting the shares roughly 7.6% in premarket trading. The full-year 2026 adjusted earnings outlook remains $19.50 to $20.00 per share following the earlier upward revision. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.

Market Reaction and Investor Sentiment

Investor sentiment ahead of the report appears measured and generally positive. Analysts maintain a largely bullish stance on UNH, with most assigning a Buy rating and price targets sitting comfortably above recent trading levels. There is confidence that third-quarter medical cost and earnings targets remain attainable, with some highlighting potential upside from the Optum Health segment. Potential risks include medical cost inflation, continued attrition in Medicare Advantage membership, and ongoing pressure on Medicaid margins, which management has described as still negative. Options activity suggests traders anticipate a noticeable move after the release, consistent with the stock's past patterns around earnings.

Forward Outlook and Key Factors to Monitor

Outside the headline numbers, several operating details deserve close attention. The medical care ratio, which tracks medical costs relative to premium revenue, improved to 86.7% in the second quarter from 89.4% a year earlier. A stable or better reading here would reinforce the margin-expansion story.

Enrollment trends matter as well. UnitedHealthcare has been intentionally reducing its Medicare Advantage and Medicaid membership, with prior guidance pointing to a potential decline of roughly 1.1 million Medicare Advantage members for the year. Investors will seek signs that this right-sizing effort is leveling off and that pricing measures are effectively offsetting the lost members.

Within Optum, focus will turn to Optum Health's value-based care progress and Optum Rx's shift toward a transparent, fee-based pharmacy approach. Both areas support longer-term growth plans.

Guidance updates will carry particular weight. With the company already targeting full-year adjusted earnings of $19.50–$20.00 per share, any adjustment could influence the post-earnings stock move. Commentary on 2027 Medicare Advantage star ratings and their revenue implications will also receive careful review.

Exploring AI Tools for Earnings Research

From what I see, incorporating data-driven tools has become a practical part of staying ahead of earnings seasons. I recently turned to Tickeron's AI Screener to scan for comparable healthcare names and review technical setups around upcoming reports. The platform allows filtering by fundamentals, patterns, and signals, which helps surface ideas efficiently when preparing for events like this one. It has proven useful for identifying context without replacing traditional analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UNH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


UNH's RSI Oscillator is staying in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UNH as a result. In 56 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.

The Moving Average Convergence Divergence Histogram (MACD) for UNH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 27 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.

UNH moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for UNH crossed bearishly below the 50-day moving average on November 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.

The Aroon Indicator for UNH entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.594) is normal, around the industry mean (3.520). P/E Ratio (25.266) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of hospital and medical service plans

Industry ManagedHealthCare

Industry
Managed Health Care
Address
1 Health Drive
Phone
+1 800 328-5979
Employees
390000
Web
https://www.unitedhealthgroup.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.